The rVSV-ZEBOV Vaccine: How Ebola's First Approved Vaccine Works
A research guide to the rVSV-ZEBOV (Ervebo) Ebola vaccine — its development, mechanism of action, efficacy data, ring vaccination strategy, and limitations.
Background
For decades, there was no approved vaccine for Ebola. The 2014–2016 West Africa epidemic created the political and scientific urgency to accelerate development. The result was rVSV-ZEBOV (recombinant vesicular stomatitis virus–Zaire Ebola virus), commercially named Ervebo, developed by Merck.
Ervebo received FDA approval in December 2019 and EMA approval in November 2019, making it the first licensed Ebola vaccine in history.
How It Works
rVSV-ZEBOV is a live, attenuated recombinant vaccine. It uses the vesicular stomatitis virus (VSV) as a vector — an animal virus that is not pathogenic in humans — engineered to express the Zaire ebolavirus glycoprotein (GP).
When injected, the modified VSV infects cells and displays the Ebola GP on its surface. The immune system recognises this as foreign and mounts a response:
- Innate immune response: rapid, non-specific defence
- Adaptive response: T-cell and B-cell activation targeting Ebola GP
- Memory formation: long-lasting immunity (demonstrated up to 2 years in trials)
The vaccine is administered as a single dose intramuscularly.
Efficacy Data
The pivotal Ebola Ça Suffit ring vaccination trial (Guinea, 2015) demonstrated 100% efficacy in the immediate vaccination group (vaccinated within 0–3 days of contact) with no cases in 2,108 participants.
The 2018–2020 DRC North Kivu outbreak provided real-world validation: over 300,000 people vaccinated under WHO’s Expanded Access/Compassionate Use protocol, with ring vaccination covering contacts and contacts-of-contacts.
| Trial | Setting | Efficacy |
|---|---|---|
| Ebola Ça Suffit (2015) | Guinea | ~100% (immediate vaccination) |
| DRC Compassionate Use (2018-20) | North Kivu | High effectiveness confirmed |
| Phase III PALM trial | DRC | Supported licensure |
Ring Vaccination Strategy
rVSV-ZEBOV is deployed using a ring vaccination approach:
- Identify a confirmed case (“index case”)
- Map all contacts within 21 days
- Vaccinate contacts and contacts-of-contacts
- The “ring” of immunity breaks the transmission chain
This targeted approach is more logistically feasible in conflict and resource-limited settings than mass vaccination.
Limitations
- Zaire ebolavirus only: Ervebo does not protect against Sudan, Bundibugyo, Tai Forest, or other Ebola species
- Cold chain requirement: Must be stored at -60°C to -80°C — extremely challenging in remote DRC
- Pregnancy: Initially excluded from trials; now recommended for pregnant women under WHO guidance
- No Sudan ebolavirus vaccine: The 2022 Uganda outbreak (Sudan strain) had no approved vaccine available
The Sudan Ebolavirus Gap
The 2022 Uganda outbreak highlighted a critical gap: no licensed vaccine exists for Sudan ebolavirus. Several candidates are in development, including:
- cAd3-EBO S (Oxford/GSK): Phase 2 trials initiated after Uganda 2022
- MVA-BN Filo: Bayarian Nordic candidate in clinical trials
The absence of a Sudan vaccine remains a significant global health security vulnerability.
Conclusion
rVSV-ZEBOV/Ervebo is a highly effective tool for controlling Zaire ebolavirus outbreaks when deployed rapidly with ring vaccination. Its development in under 5 years from the 2014 epidemic to licensure was a landmark achievement. The challenge now is extending coverage to other Ebola species and improving cold chain logistics in outbreak settings.